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Approximately 170 million people are infected with hepatitis C, and the sustained virological
response rate to treatment with pegylated interferon and ribavirin is 30–50%. In an attempt
to  improve the chances of cure, boceprevir is being added to therapy, but it is associated with
an  increased incidence of adverse events. We  herein report a case of acute pancreatitis devel-
oped  during treatment with pegylated interferon, ribavirin and boceprevir. Boceprevir was
the most likely cause of drug-associated pancreatitis after the most common causes were
ruled out, since this adverse event had not occurred when the patient had previously been
exposed to pegylated interferon and ribavirin and there was no recurrence of the episode of
pancreatitis when these two drugs were reintroduced. Acute pancreatitis is a rare adverse
event associated with boceprevir therapy, but a potentially fatal event. Sequential deter-mination of pancreatic enzymes should be considered during hepatitis C treatment with
boceprevir.
©  2014 Elsevier Editora Ltda. All rights reserved.Introduction
An estimated 170 million people worldwide are chronically
infected with hepatitis C virus (HCV).1 The sustained viro-
logical response (RVS) rate to combination treatment with
pegylated interferon and ribavirin for HCV genotype 1 ranges
from 30 to 50%.2 In an attempt to improve the chances
of cure, new drugs were developed and used in combina-
tion with pegylated interferon and ribavirin. One of the two
recently approved direct-acting antiviral agents is boceprevir,
∗ Corresponding author at: Rua Izabel Gimenez Fante, 51, Quinta do Go
E-mail address: jmbilar@gmail.com (J.M. Bilar).
http://dx.doi.org/10.1016/j.bjid.2014.03.008
1413-8670/© 2014 Elsevier Editora Ltda. All rights reserved.a protease inhibitor that blocks viral replication by binding
reversibly to the viral protease NS3.3
The addition of boceprevir to pegylated interferon and
ribavirin increased the chance of a SVR (63–66% in treatment-
naive patients and 52–75% in previously treated patients),4,5
but it also was associated with an increased incidence of
adverse events during treatment, especially anemia and
dysgeusia.4,5
We  report the case of a patient with acute pancreatitis asso-
ciated with boceprevir therapy. Informed consent has been
obtained.lfe, 15093-307, São José do Rio Preto, São Paulo, SP, Brazil.
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ase  report
 43-year-old white man  was admitted to the Hepatitis Unit
f the Federal University of São Paulo, Brazil, in May 1995
or the investigation of liver disease due to the ﬁnding of
chronic hepatitis caused by HCV” in an intraoperative liver
iopsy obtained one month earlier. The patient had undergone
holecystectomy for symptomatic gallstones and reported
o other comorbidities or surgeries. The patient had used
llicit drugs in the past, has been smoking since he was
0 years old, and reported no alcohol abuse. The diagno-
is of chronic hepatitis C was conﬁrmed by the detection
f HCV RNA. Re-examination of the liver biopsy classiﬁed
he specimen as F1A2 according to the METAVIR scoring
ystem. The patient received conventional interferon for
ix months until October 1996 and was considered a non-
esponder.
In 2006, genotype 1 was detected and analysis of a new
ercutaneous liver biopsy revealed F2A3. The patient received
 second course of pegylated interferon alfa 2a (180 g,
ubcutaneously, once a week) and ribavirin (1.0 g per day,
rally) for 48 weeks and again did not respond to treat-
ent.
In 2012, noninvasive examinations showed no evidence
f advanced ﬁbrosis and the patient started the third treat-
ent with pegylated interferon alfa 2b (1.5 g, subcutaneously,
nce a week), ribavirin (1.250 g per day, orally), and bocepre-
ir (800 mg,  orally, three times per day). The viral load at
he beginning of treatment was 2,200,000 IU/mL (6.34 log) and
oceprevir was administered after a 4-week lead-in period.
he viral load remained at 2,360,000 IU/mL (6.37 log) after the
ead-in period but was undetectable after 8 and 12 weeks of
reatment and the patient presented only mild ﬂu-like symp-
oms.
After 17 weeks of treatment (13 weeks on boceprevir), the
atient was hospitalized with epigastric pain radiating to the
ack, nausea, and vomiting. The patient reported no alcohol
onsumption or use of other medications. Laboratory tests at
dmission showed hemoglobin 14 g/L, hematocrit 43, leuko-
ytes 5700 mm3, platelets 163,000 mm3, amylase 1209 IU/mL
normal: up to 125 IU/mL), lipase 6462 IU/mL (normal: up to
0 IU/mL), aspartate aminotransferase 34 IU/mL (normal: up
o 40 IU/mL), alanine aminotransferase 42 IU/mL (normal: up
o 42 IU/mL), total Ca 9.0 mg/dL, ionized Ca 4.5 mg/dL, and
riglycerides 195 mg/dL. Upper abdominal computed tomogra-
hy only revealed absence of gallbladder (cholecystectomy).
uclear magnetic resonance imaging of the upper abdomen
howed a pancreas of normal size, with a zone of altered sig-
al in the pancreatic head close to the papilla, measuring
.5 cm.
The hypothesis of drug-associated pancreatitis was
aised after the most common causes had been ruled
ut. Cholelithiasis and choledocholithiasis were excluded
ince the patient had undergone cholecystectomy in the
ast and the upper abdominal computed tomography did
ot reveal any change in the biliary tree. Alcohol asso-
iated pancreatitis was also ruled out since the patient
enied alcohol consumption. Elevated calcium or trigly-
erides were not possible causes of pancreatitis, as both4;1 8(4):454–456 455
were within the normal range. Pegylated interferon, ribavirin
and boceprevir were immediately discontinued and support-
ive care was initiated. The patient was discharged after
two days with clinical improvement and amylase levels of
82 IU/mL.
On the follow-up visit to the outpatient clinic one week
after discharge, the patient was asymptomatic and pancreatic
enzyme levels were within the normal range, with amylase
levels of 101 IU/mL and lipase levels of 101 IU/mL. On that occa-
sion, pegylated interferon and ribavirin were reintroduced at
the same doses as administered previously and the patient
only developed mild ﬂu-like symptoms. No symptoms sugges-
tive of pancreatitis or new elevations of pancreatic enzymes
were observed.
Treatment was discontinued at week 26 because HCV RNA
had been detected at week 24 and the patient again was con-
sidered a non-responder. The patient remained asymptomatic
six months after the end of treatment, without recurrence of
pancreatitis.
Conclusion
This is the ﬁrst report describing the association of acute pan-
creatitis and boceprevir. Recently, the ﬁrst report describing
drug-associated pancreatitis during triple therapy for hepati-
tis C with telaprevir was published,6 indicating the need for
constant monitoring of pancreatic enzymes during treatment
with these new drugs.
In the present case, the patient was eligible for triple ther-
apy since he had not responded to two previous treatments,
one consisting of conventional interferon and the other of
pegylated interferon plus ribavirin. In both treatments, the
patient developed ﬂu-like symptoms and mild anemia as
adverse events.
During treatment with pegylated interferon, ribavirin and
boceprevir, the patient was diagnosed with acute pancreatitis
based on the criteria of the American College of Gastro-
enterology, which deﬁne the condition when two  of three
criteria are present: (1) abdominal pain characteristic of pan-
creatitis, (2) serum amylase and/or lipase ≥3× upper limit of
normal, and (3) computed tomography suggestive of acute
pancreatitis.7 The most common causes of acute pancreati-
tis, such as cholelithiasis, alcohol abuse, hypercalcemia and
hypertriglyceridemia, were ruled out by tests performed on
admission.
Drugs are less frequent causes of acute pancreatitis,
responsible for 0.1%8 to 5.3%.9 The diagnosis of drug-induced
pancreatitis requires the development of the condition dur-
ing treatment with the suspected drug and the resolution
of symptoms after discontinuation of the drug, an adequate
criterion for the diagnosis of acute pancreatitis, and the
absence of other common causes of pancreatitis.10 Accord-
ing to the classiﬁcation of Karchand Lasagna11 published
in 1975 and of Mallory and Kern12 published in 1980, the
association between a drug and acute pancreatitis is def-
inite when there is recurrence of the adverse event after
challenging with the suspected drug. The latter is rarely
seen due to the fear of reappearance of a potentially seri-
ous adverse event. In most cases, the causal relationship is
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classiﬁed as probable since the symptoms disappear after
discontinuation of the drug, as observed in the present
case.
Acute pancreatitis is a rare adverse event in registry
studies of boceprevir. The SPRINT-2 study evaluated the efﬁ-
cacy and safety of boceprevir in treatment-naive patients
with hepatitis C.4 Acute pancreatitis was observed in one
(<1%) of the 734 subjects exposed to the drug. In the
RESPOND-2 study, which evaluated boceprevir for the retreat-
ment of patients with hepatitis C, acute pancreatitis was
observed in 2 (<1%) of the 323 patients who received
boceprevir.5
In the present case, pancreatitis was most likely associ-
ated with boceprevir therapy since this adverse event had
not occurred when the patient had previously been exposed
to pegylated interferon and ribavirin. Pegylated interferon
and ribavirin were reintroduced one week after clinical
improvement and there was no recurrence of the episode
of pancreatitis, lending support to the possibility that these
drugs were not involved in the development of pancreatitis in
this patient.
According to the Naranjo algorithm, which is used to
estimate the probability of drug-induced adverse events,13
boceprevir was a probable drug associated with pancreatitis
in the present case. Another ﬁnding supporting the causal
relationship between boceprevir and acute pancreatitis is
the fact that the patient did not develop pancreatitis prior
to the use of boceprevir or during the 6-month observa-
tion period after the end of treatment. Other less common
causes of acute pancreatitis, such as biliary microlithia-
sis and autoimmune pancreatitis, could therefore be ruled
out.
In conclusion, boceprevir has recently been introduced for
the treatment of chronic hepatitis C, and will be used in a large
number of patients. One of the side effects associated to this
drug is acute pancreatitis which, although rare, is a potentially
fatal event. We  suggest that the sequential determination of
pancreatic enzymes should be considered during hepatitis C
treatment with boceprevir in order to allow for early diagnosis
of acute pancreatitis.
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